Literature DB >> 21106849

Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.

Anik L Côté1, Peisheng Zhang, Jeremy A O'Sullivan, Valerie L Jacobs, Carli R Clemis, Shimon Sakaguchi, José A Guevara-Patiño, Mary Jo Turk.   

Abstract

Treatment of tumor-bearing mice with a stimulatory Ab to glucocorticoid-induced TNFR family-related receptor (GITR) has previously been shown to elicit protective T cell responses against poorly immunogenic tumors. However, the role of GITR stimulation on CD8 T cells and the nature of tumor rejection Ags have yet to be determined. In this study, we show that a stimulatory mAb to GITR (clone DTA-1) acts directly on CD8 T cells, but not on CD4(+)CD25(+) regulatory T (T(reg)) cells, in B16 tumor-bearing mice to induce concomitant immunity against secondary B16 tumors, as well as protective memory following surgical excision of the primary tumor. Melanoma growth itself induced GITR expression on tumor-specific CD8 T cells, providing a mechanism whereby these cells may respond to stimulatory anti-GITR. Unexpectedly, in contrast to T(reg) cell depletion therapy with anti-CD4, GITR stimulation induced very weak CD8 T cell responses to melanocyte differentiation Ags expressed by the tumor, and did not induce autoimmune vitiligo. Accordingly, GITR-stimulated hosts that were primed with B16 melanoma rejected B16, but not the unrelated JBRH melanoma, indicating that tumor rejection Ags are tumor-specific rather than shared. In support of this, we show that GITR stimulation induces CD8 T cell responses to a tumor-specific Ag, and that these responses are of higher functional avidity compared with those induced by T(reg) cell depletion. We conclude that stimulation of GITR on effector CD8 T cells results in high-avidity T cell responses to tumor-specific Ags, thereby inducing potent antitumor immunity in the absence of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106849      PMCID: PMC3050990          DOI: 10.4049/jimmunol.1001308

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  Antigens for cancer immunotherapy.

Authors:  Michelle A Neller; J Alejandro López; Christopher W Schmidt
Journal:  Semin Immunol       Date:  2008-10-23       Impact factor: 11.130

2.  Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours.

Authors:  Jinhua Piao; Yosuke Kamimura; Hideyuki Iwai; Yujia Cao; Keisuke Kikuchi; Masaaki Hashiguchi; Taro Masunaga; Hongsi Jiang; Kouichi Tamura; Shimon Sakaguchi; Miyuki Azuma
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

3.  GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo.

Authors:  Ronald W van Olffen; Nathalie Koning; Klaas P J M van Gisbergen; Felix M Wensveen; Robert M Hoek; Louis Boon; Jörg Hamann; Rene A W van Lier; Martijn A Nolte
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

4.  Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.

Authors:  D Boczkowski; J Lee; S Pruitt; S Nair
Journal:  Cancer Gene Ther       Date:  2009-06-05       Impact factor: 5.987

5.  Immune rejection of mouse tumors expressing mutated self.

Authors:  Fei Duan; Yun Lin; Cailian Liu; Manuel E Engelhorn; Adam D Cohen; Michael Curran; Shimon Sakaguchi; Taha Merghoub; Stephanie Terzulli; Jedd D Wolchok; Alan N Houghton
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells.

Authors:  Shuming Chen; Lishomwa C Ndhlovu; Takeshi Takahashi; Kazuyoshi Takeda; Yoshinori Ikarashi; Toshiaki Kikuchi; Kazuko Murata; Pier Paolo Pandolfi; Carlo Riccardi; Masao Ono; Kazuo Sugamura; Naoto Ishii
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

Review 7.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

8.  Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity.

Authors:  Katrin M Baltz; Matthias Krusch; Tina Baessler; Benjamin J Schmiedel; Anita Bringmann; Peter Brossart; Helmut R Salih
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

9.  Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.

Authors:  Hiroyoshi Nishikawa; Takuma Kato; Michiko Hirayama; Yuki Orito; Eiichi Sato; Naozumi Harada; Sacha Gnjatic; Lloyd J Old; Hiroshi Shiku
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation.

Authors:  Zuqiang Liu; Shenghe Tian; Louis D Falo; Shimon Sakaguchi; Zhaoyang You
Journal:  Mol Ther       Date:  2009-05-05       Impact factor: 11.454

View more
  20 in total

Review 1.  Targeting regulatory T cells in cancer.

Authors:  William L Byrne; Kingston H G Mills; James A Lederer; Gerald C O'Sullivan
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

2.  T cell avidity and tumor immunity: problems and solutions.

Authors:  Arthur A Hurwitz; Steven M Cuss; Katherine E Stagliano; Ziqiang Zhu
Journal:  Cancer Microenviron       Date:  2013-12-20

Review 3.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

Review 4.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

Review 5.  Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.

Authors:  Ronald J Fecek; Walter J Storkus
Journal:  Immunotherapy       Date:  2016-10       Impact factor: 4.196

Review 6.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

7.  Th2 responses to helminth parasites can be therapeutically enhanced by, but are not dependent upon, GITR-GITR ligand costimulation in vivo.

Authors:  Nienke van der Werf; Stephen A Redpath; Alexander T Phythian-Adams; Miyuki Azuma; Judith E Allen; Rick M Maizels; Andrew S Macdonald; Matthew D Taylor
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

8.  Murine B cell development and antibody responses to model antigens are not impaired in the absence of the TNF receptor GITR.

Authors:  Lenka Sinik Teodorovic; Carlo Riccardi; Raul M Torres; Roberta Pelanda
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

Review 9.  New perspectives on the role of vitiligo in immune responses to melanoma.

Authors:  Katelyn T Byrne; Mary Jo Turk
Journal:  Oncotarget       Date:  2011-09

Review 10.  CD8+ T cells: GITR matters.

Authors:  Simona Ronchetti; Giuseppe Nocentini; Maria Grazia Petrillo; Carlo Riccardi
Journal:  ScientificWorldJournal       Date:  2012-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.